治疗自身免疫性心肌炎药物实验研究进展  

Advance of experimental drug for treatment of autoimmune myocarditis

作　　者：林娜[1] 李亚伦[2] 常天辉[2] 

机构地区：[1]中国医科大学附属第一医院血液科,沈阳110001 [2]中国医科大学药学院临床药理教研室,沈阳110001

出　　处：《中国新药杂志》2008年第5期359-363,共5页Chinese Journal of New Drugs

基　　金：卫生部重点基金(88402257)

摘　　要：自身免疫性心肌炎进展快,复发率高,可导致严重心律失常、心源性休克和充血性心力衰竭等。临床上还没有确切有效的药物,主要以对症处理为主。近年来国内外从不同的角度开展了大量关于治疗该病药物的实验研究,如抑制炎症因子或共刺激分子的基因靶向治疗、调节氧化还原反应药物、调节Th1/Th2炎症因子分泌药物、抑制心肌重构药物的探索与开发等。现就治疗该病药物实验研究进展予以综述,以指导药物临床试验与应用,并为未来该领域进一步研究提供参考。Autoimmune myocarditis develops rapidly with a high rate of recurrence, and usually induces severe arrhythmia, cardiogenic shock, congestive heart failure, etc. However, autc.immune myocarditis is treated only by symptomatic therapy. There are still no effective drugs available. Lots of experimental researches have been done for its drug therapy from different aspects worldwide in recent years, such as gene targeting therapy on inhibition of inflammatory cytokine or costimulatory molecules, exploring drugs of redox regulation, balancing Th1/Th2 cytokine secretion, reducing myocardial reconstruction, and so on. This article reviewed the research status of experimental drug research in the treatment of autoimmune myocarditis, which may be useful for drug clinical trials and practice in this field.

关 键 词：自身免疫 心肌炎 药物治疗 实验性自身免疫性心肌炎 

分 类 号：R967[医药卫生—药理学] R593[医药卫生—药学]